NCT03297996

Brief Summary

Gut microbiota were assessed in 540 colonoscopy-screened adults by 16S rRNA gene sequencing of stool samples. Investigators compared gut microbiota diversity, overall composition, and normalized taxon abundance among these groups.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
540

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Nov 2011

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 23, 2011

Completed
3.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 25, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 25, 2015

Completed
2.4 years until next milestone

First Submitted

Initial submission to the registry

September 27, 2017

Completed
2 days until next milestone

First Posted

Study publicly available on registry

September 29, 2017

Completed
Last Updated

September 29, 2017

Status Verified

September 1, 2017

Enrollment Period

3.4 years

First QC Date

September 27, 2017

Last Update Submit

September 28, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • Prevalence and relative abundance of selected fecal microbial taxa

    Quantitative polymerase chain reaction

    2 Days

Study Arms (2)

SIT

Centers for Disease Control and Prevention (CDC) Study of In-home Tests for Colorectal Cancer (SIT)

Diagnostic Test: Mobio PowerSoil DNA Isolation Kit

NYU

New York University (NYU) Human Microbiome and Colorectal Tumor study

Diagnostic Test: Mobio PowerSoil DNA Isolation Kit

Interventions

16S rRNA amplicons covering variable regions V3 to V4 were generated using primers (347F-5'GGAGGCAGCAGTRRGGAAT'-3' and 803R 5'-CTACCRGGGTATCTAATCC-3') incorporating Roche 454 FLX Titanium adapters (Branford, CT) and a sample barcode sequence

NYUSIT

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

There are no enrollment restrictions based on race or ethnic origins. Vulnerable subjects such as pregnant women and children will not be involved in this study. We will not ask subjects about sensitive topics such as Mental Health, drug/alcohol abuse, or others that fall in this category.

You may qualify if:

  • Both men and women who have visited a gastroenterologist or surgeon, aged 18 or older will be included in this study.
  • Both men and women residents in the United States, aged 18 or older will be included in this study.

You may not qualify if:

  • Women who are pregnant will be excluded from participating in this study
  • Subjects on ongoing antibiotic therapy will be excluded from participating in this study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

New York University School of Medicine

New York, New York, 10016, United States

Location

Biospecimen

Retention: SAMPLES WITH DNA

DNA was extracted from stool using the PowerLyzer PowerSoil Kit (Mo Bio Laboratory Inc., CA) following the manufacturer's protocol. DNA was collected and eluted using silica columns included with the PowerLyzer PowerSoil kit. Barcoded amplicons were generated covering the V4 region of the 16S rRNA gene using the F515/R806 primer pair.

MeSH Terms

Conditions

Colorectal Neoplasms

Condition Hierarchy (Ancestors)

Intestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal DiseasesRectal Diseases

Study Officials

  • Jiyoung Ahn, MD

    NYU Langone Health

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 27, 2017

First Posted

September 29, 2017

Study Start

November 23, 2011

Primary Completion

April 25, 2015

Study Completion

April 25, 2015

Last Updated

September 29, 2017

Record last verified: 2017-09

Locations